Analysis method of senescence biomarkers based on glycoproteomics and phosphoproteomics

The method addresses high cross-talk in existing glycoproteomics and phosphoproteomics analysis by optimizing sample pretreatment and enrichment techniques, achieving efficient and accurate biomarker discovery from limited samples.

CN119086796APending Publication Date: 2024-12-06赣江中药创新中心
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411304040.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing methods for simultaneous enrichment and separation of glycopeptides and phosphorylated peptides suffer from high cross-talk and interference, leading to inefficient analysis of aging biomarkers due to mutual interference between different fractions, and require large sample amounts for independent analysis.

Method used

A method for analyzing aging biomarkers through clinical sample pretreatment, liquid phase-tandem mass spectrometry, and database retrieval, involving specific enrichment processes for glycopeptides and phosphorylated peptides using solid phase extraction, followed by mass spectrometry analysis and database screening to minimize cross-talk.

Benefits of technology

The method provides efficient, stable, and accurate analysis of glycoproteomics and phosphoproteomics data with minimal interference, enabling the discovery of aging biomarkers from limited samples and facilitating large cohort analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005048580080000011
    Figure HDA0005048580080000011
  • Figure HDA0005048580080000012
    Figure HDA0005048580080000012
  • Figure HDA0005048580080000013
    Figure HDA0005048580080000013
Patent Text Reader

Abstract

The invention discloses an analysis method of senescence biomarkers based on glycoproteomics and phosphoproteomics, relates to the field of senescence biomarkers, and specifically comprises a liquid phase-tandem mass spectrometry analysis process, a database retrieval process and a senescence marker screening process. Wherein in the liquid phase-tandem mass spectrometry analysis process, a sample of a clinical biological sample is pretreated, namely a protein extraction process and an enzymolysis process of the clinical sample and an enrichment process of glycopeptide and phosphorylated peptide are included; on one hand, the unreasonability of high intersectionality of glycoprotein and phosphorylated protein in the existing technology for simultaneously analyzing glycoprotein and phosphorylated protein is solved; on the other hand, a more comprehensive protein post-translational modification data set can be obtained under the limited sample amount, the use amount of precious samples is reduced, and it is guaranteed that post-translational modification proteomics data of biological samples is wide in identification depth and low in intersectionality; and batch continuous analysis of a glycoprotein group and a phosphorylated proteome of a trace protein sample can be realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomarkers, and in particular to an analysis method for aging biomarkers based on glycoproteomics and phosphorylated proteomics. Background Art

[0002] Aging is the biggest risk factor for most chronic diseases, cognitive impairment, and death. As the aging population continues to grow worldwide, research on aging-targeted treatments to extend healthy lifespan has received increasing attention. Although multi-omics studies such as genomics, transcriptomics, and metabolism have provided many important biological insights into the mechanisms of aging, changes in single DNA, RNA, or metabolite levels are not sufficient to explain the complex pathological mechanisms of aging. Proteins are the direct executors of many biological processes, and the diversity of protein functions is mainly regulated by their post-translational modifications (PTMs). Therefore, proteomics and post-translational modification proteomics are expected to provide more valuable insights into aging and age-related diseases. Glycosylation and phosphorylation are among the most common and critical post-translational modifications. Abnormal protein glycosylation and phosphorylation are closely related to aging, and these two post-translational modifications often interact with each other to jointly regulate various biological processes. For example, the main pathological feature of the aging-related disease Alzheimer's disease is the hyperphosphorylation of tau protein, and abnormal N-glycosylation of tau can trigger its hyperphosphorylation, forming neurofibrillary tangles, leading to neuronal death and cognitive dysfunction. Therefore, simultaneous monitoring of these two post-translational modifications and elucidating their interactions are of great significance for understanding the molecular changes that occur during aging. However, due to the highly complex molecular programs in the aging process and the extremely low abundance of post-translationally modified peptides, sample pre-treatment techniques pose a huge challenge.

[0003] In recent years, a variety of methods for enriching glycopeptides in complex biological samples have been developed and applied. For example, lectin affinity chromatography recognizes and enriches glycopeptides through specific lectin carbohydrates; titanium dioxide (TiO 2 ) selectively enriches glycopeptides through coordination; strong cation exchange chromatography (SCX) enriches glycopeptides through charge interactions; hydrophilic interaction chromatography (HILIC) has specific adsorption of glycopeptides through its high hydrophilicity. The enrichment methods for phosphorylated peptides mainly include metal oxide chromatography (MOAC) and immobilized metal ion chromatography (IMAC).

[0004] Existing methods for simultaneous enrichment and separation of glycopeptides and phosphorylated peptides are mainly divided into two strategies. The first strategy uses the same bifunctional material to capture glycopeptides and phosphorylated peptides at the same time, and then uses elution solutions with different conditions to achieve sequential elution. 4+-iMAC has been used to simultaneously enrich phosphorylated peptides, sialylated glycopeptides, neutral glycopeptides, and mannose-6-phosphate glycopeptides, and step-wise elution was used to separate glycopeptides with different glycan compositions from phosphorylated peptides into different elution fractions; in addition, a new multifunctional bimetallic zirconium organic framework material, using Zr 4+ The charge effect and hydrophilicity of the two materials are used for the simultaneous enrichment of phosphorylated peptides and glycopeptides. The second strategy uses a mode of connecting two materials in series to sequentially enrich and separate glycopeptides and phosphorylated peptides. Among them, Chen et al. developed a tandem IMAC-HILIC method for the simultaneous analysis of plant phosphoproteomics and glycoproteomics, combining S-Trap, IMAC and HILIC into an integrated device based on a pipette tip, which can eliminate contaminants in plant extracts and analyze glycopeptides and phosphorylated peptides at the same time; Zhou et al. developed a workflow for IMAC and MAX tandem enrichment, first using Fe 3+ -IMAC captures phosphorylated peptides, followed by MAX enrichment of the IMAC flow-through to obtain N-glycopeptides.

[0005] Research focusing only on a single post-translational modified peptide is not enough to fully understand the interaction between glycosylation and phosphorylation, and loses the correlation between post-translational modification groups; and independent and parallel analysis of post-translational modification groups requires a large amount of starting sample and multiple batches of sample pre-treatment, which will lead to a waste of precious biological samples.

[0006] The simultaneous enrichment of glycopeptides and phosphorylated peptides on the same bifunctional material will inevitably lead to mutual interference between different fractions, increasing the crossover and overlap between glycopeptides and phosphorylated peptides. In the IMAC-HILIC and IMAC-MAX tandem methods based on IMAC materials, the principle is based on the co-enrichment and step-by-step separation of glycopeptides and phosphorylated peptides by IMAC materials. However, since IMAC materials not only have a large amount of chelated Ti 4+ Ions can enrich phosphorylated peptides through electrostatic interaction, and their surface also contains a large number of highly hydrophilic hydroxyl and amine groups, which can enrich glycopeptides through hydrophilic interactions. Therefore, hydrophilic glycopeptides, especially negatively charged sialylated glycopeptides, are also highly adsorbed on IMAC materials and tend to co-elute with phosphorylated peptides, resulting in a large overlap between glycopeptides and phosphorylated peptides in the elution fractions of the IMAC material. Summary of the invention

[0007] The purpose of the present invention is to solve at least one of the technical problems existing in the prior art, and to provide an analysis of aging biomarkers based on glycoproteomics and phosphoproteomics. That is, it solves the unreasonable problem of high cross-talk between the existing glycoprotein and phosphoproteomics analysis technologies.

[0008] The technical solution of the present invention is as follows:

[0009] A method for analyzing aging biomarkers based on glycoproteomics and phosphoproteomics, including: clinical biological sample pretreatment, liquid phase-tandem mass spectrometry analysis process, database retrieval process and aging marker screening process; specifically:

[0010] First, the clinical biological samples of different age groups were pre-treated to obtain glycoproteomics samples and phosphoproteomic samples. Liquid chromatography-mass spectrometry was used to detect and analyze the glycoproteomics samples and phosphoproteomic samples to obtain mass spectrometry data. Then, database retrieval, qualitative and quantitative analysis of glycopeptides and phosphopeptides were performed on the mass spectrometry data. The quantitative values ​​of glycopeptide or phosphopeptide abundance obtained by the search software were filtered and interpolated for missing values, log2 transformed, and analyzed for significant differences.

[0011] The pre-treatment of the clinical biological sample includes: a protein extraction process, an enzymatic hydrolysis process and a glycopeptide and phosphorylated peptide enrichment process of the clinical biological sample.

[0012] As a preferred embodiment of the present invention, the clinical biological sample pretreatment comprises the following steps:

[0013] S1: Select clinical biological samples of different age groups, perform ultrasonic disruption and protein extraction in a protein denaturing solution, perform reduction alkylation reaction on the extracted proteins, and then add protease to enzymatically hydrolyze the samples to obtain enzymatic peptide samples of clinical biological samples;

[0014] S2: After the enzymatic peptide sample is spin-dried and desalted by C18, it is redissolved in the equilibrium solution system, and the glycopeptide enrichment material is loaded into the pipette tip or gel loading tip to form an SPE solid phase extraction column; after equilibrating the material with the equilibrium solution, the enzymatic peptide sample is loaded into the SPE column, and the SPE column is rinsed with 5-200 column volumes of the equilibrium solution to remove the phosphorylated peptides and non-modified peptides thereon; at the same time, the sample solution in the enrichment process is collected and combined with the eluent; 5-10 The glycopeptide is eluted with 0 column volume of glycopeptide eluent; or when enriching glycopeptides in dSPE mode, the enzymatic peptide sample is directly mixed with the glycopeptide enrichment material, incubated for 0.5-60 minutes, centrifuged, the material is washed with the balance solution, centrifuged, and the sample solution and the eluent in the enrichment process are collected and combined; the glycopeptide is then eluted with the glycopeptide eluent; the glycopeptide eluate obtained by solid phase extraction mode (SPE) or dispersed solid phase extraction mode (dSPE) is the glycoproteomics sample after being spin-dried;

[0015] S3: Load the phosphorylated peptide enrichment material into the pipette tip or gel loading tip to form an SPE solid phase extraction column; use the equilibration liquid equilibration material to adjust the combined glycopeptide loading solution and eluent system in step S2 to the equilibration liquid solvent system of the phosphorylated peptide material, load it into the SPE column, and use 5-200 times the column volume of the equilibration liquid to wash the SPE column to remove the non-modified peptides thereon; use 5-100 times the column volume of the phosphorylated peptide eluent to elute the phosphorylated peptide; or when enriching phosphorylated peptides in the dSPE mode, adjust the combined glycopeptide loading solution and eluent system to the equilibration liquid solvent system of the phosphorylated peptide material and directly mix it with the phosphorylated peptide enrichment material, incubate for 0.5-60 minutes, centrifuge, wash the material with the equilibration liquid, and centrifuge; then use the phosphorylated peptide eluent to elute the glycopeptide; the phosphorylated peptide eluent obtained by the solid phase extraction mode (SPE) or the dispersed solid phase extraction mode (dSPE) is the phosphorylated proteomics sample after being spin-dried.

[0016] As a preferred embodiment of the present invention, in step S1, the clinical biological sample is at least one of a tissue, a body fluid, a plasma, a serum and a cell line of a mammal, and the mammals include at least two age groups.

[0017] As a preferred solution of the present invention, step S1 includes at least one of the following technical features:

[0018] The protein denaturing solution comprises at least one of 5-100 mM ammonium bicarbonate solution, 0-8 M urea, 0-8 M guanidine hydrochloride, 0%-10% SDS, and 1-2% by volume of a protease inhibitor;

[0019] The reductive alkylation reaction includes a reduction process and an alkylation process. The reduction process uses a 5-100 mM ammonium bicarbonate solution containing 5-50 mM dithiothreitol or tris(2-carboxyethyl)phosphine hydrochloride to react for 5-120 minutes at room temperature or under heating; the alkylation process specifically uses a 5-100 mM ammonium bicarbonate solution containing 5-50 mM iodoacetamide or chloroacetamide to react for 5-60 minutes at room temperature in the dark.

[0020] As a preferred embodiment of the present invention, in step S1, the protease is one or more combinations of trypsin, chymotrypsin, lysyl endonuclease, thermolysin, proteinase K, and glutamyl protein endonuclease; the mass ratio of protease to protein is controlled between 1:1-1:50; at the same time, the enzyme cleavage time is adjusted to 30min-24h; the enrichment process of glycopeptides and phosphorylated peptides adopts solid phase extraction mode (SPE) or dispersed solid phase extraction mode (dSPE).

[0021] As a preferred embodiment of the present invention, the glycopeptide enrichment material is a commercial hydrophilic chromatography material (such as ZIC-HILIC, TiO 2 , IMAC, etc.) or one or a combination of laboratory-made glycopeptide enrichment materials (such as Click-Mal, TE-Cys, HBS, etc.); the amount of glycopeptide enrichment material is 1-10 mg; the mass ratio of glycopeptide enrichment material to enzymatic peptide sample is 100:1-1000:1;

[0022] Phospho-peptide enrichment materials include but are not limited to commercial IMAC, TiO 2 , ZrO 2 ; The amount of phosphorylated peptide enrichment material is 1-10 mg; the mass ratio of phosphorylated peptide enrichment material to the enzymatic peptide sample of the starting clinical biological sample is 100:1-1000:1.

[0023] As a preferred embodiment of the present invention, in step S2, the glycopeptide-enriched equilibrium solution is an organic phase solution containing an organic acid, the volume concentration of the organic acid is 0.1-5%, the volume concentration of the organic phase is 60-95%, the organic acid is formic acid, acetic acid or trifluoroacetic acid, and the organic phase is acetonitrile, methanol or ethanol;

[0024] The glycopeptide enrichment eluent is an organic phase solution containing an organic acid, the volume concentration of the organic acid is 0.1-5%, the volume concentration of the organic phase is 20-55%, the organic acid is formic acid, acetic acid or trifluoroacetic acid, and the organic phase is acetonitrile, methanol or ethanol;

[0025] The equilibrium solution for enriching phosphorylated peptides is an organic phase solution containing an organic acid, wherein the volume concentration of the organic acid is 0.1-5%, the volume concentration of the organic phase is 60-95%, the organic acid is glycolic acid, formic acid, acetic acid or trifluoroacetic acid, and the organic phase is acetonitrile, methanol or ethanol;

[0026] The eluent for enriching phosphorylated peptides is 0.5-30% wt ammonia solvent.

[0027] As a preferred embodiment of the present invention, the separation and analysis process of liquid chromatography-mass spectrometry comprises using Thermo Any mass spectrometer of Fisher's Orbitrap series mass spectrometer and Bruker's TIMS-TOF mass spectrometer and a matching liquid chromatography system instrument; the liquid chromatography analysis column and pre-column adopt a conventional C18 capillary column, the capillary outer diameter is one of 100μm, 360μm, and 1mm, and the matching inner diameter is one of 10μm, 50μm, and 100μm; the capillary filling length is 10-50cm, and the C18 filler particles used are 1.7-5μm; the liquid phase mobile phase used is a mixed solvent of organic solvent, deionized water, and organic acid, the organic acid is one of formic acid, acetic acid or trifluoroacetic acid, and the volume proportion of organic acid is 0.1%-30%; the volume proportion of organic solvent is 1-80%; the chromatographic separation mode used is a reversed phase chromatographic separation mode; the mass spectrometry data acquisition mode of glycoproteomics data is a data-dependent acquisition mode (DDA), and the data acquisition mode of phosphorylation proteomics is a data-dependent acquisition mode (DDA) or a data-independent acquisition mode (DIA).

[0028] As a preferred embodiment of the present invention, the glycoproteomics data mass spectrometry data retrieval software adopts one or several combinations of Byonic software of ProteinMetrics or open source software such as pGlyco software; the phosphoproteomic data mass spectrometry data retrieval software adopts one or several combinations of Maxquant, PD software of Thermo Fisher, Spectronaut software of Biognosys or open source software such as DIA-NN; the database used is the species database corresponding to the samples used in UniProt; the filtering of missing values ​​adopts the principle that at least one of the data of the samples between the two groups has more than half of the valid values; the interpolation of missing values ​​adopts one of the K nearest neighbor method (KNN), continuous K nearest neighbor method (SeqKnn), global minimum, minimum value of each row, multiple interpolation method (MI), random forest method (MissForest) and normal distribution method; the significance test adopts Empirical Bayes t test or Student's t test; the difference multiple is obtained by the ratio of the means of the quantitative values ​​of the abundance of glycopeptides or phosphorylated peptides of sample groups of different ages after missing value filtering, interpolation and log2 transformation, wherein |log2 Peptides with fold change|>2 and p≤0.05 were considered to be age-differentiated peptides.

[0029] The beneficial effects of the present invention are as follows: on the one hand, the biological sample pretreatment method provided by the present invention solves the unreasonable high cross-talk between the existing glycoproteins and phosphorylated proteins in the technology of simultaneous analysis of the two. On the other hand, compared with the independent analysis of glycoproteomics and phosphorylated proteomics, the present invention provides an efficient, stable and highly accurate analysis method for discovering biomarkers of glycoproteins and phosphorylated proteins related to aging, which can simultaneously obtain glycoproteomics and phosphorylated proteomics data in a limited trace sample analysis of a single experiment under the premise of minimizing the cross-talk and interference between post-translationally modified peptides. This method has the potential to continuously and deeply analyze large cohort samples of multiple age groups, and the relevant results of the present invention provide clues for exploring the interaction between glycosylation and phosphorylation in the aging process. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The figure is a schematic diagram of the sample pretreatment process for simultaneous enrichment of glycopeptides and phosphorylated peptides according to the present invention.

[0031] Figure 2 The figure shows the comparison of the MS2 spectra of oxonium ions in the phosphorylated peptide fractions of the sample pretreatment method of the present invention and the IMAC-HILIC tandem method.

[0032] Figure 3 The results of phosphorylated peptide identification in the glycopeptide fractions of the sample pretreatment method of the present invention and the IMAC-HILIC tandem method are compared.

[0033] Figure 4 The target peptide identification results of the sample pretreatment method of the present invention and the IMAC-HILIC tandem method are compared.

[0034] Figure 5 The invention discloses the down-regulated expression of the sugar chain HexNAc(5)Hex(6)NeuAc(2) on the glycosylation site N1055 of the aging-related glycoprotein Egfr in the brains of mice of different ages.

[0035] Figure 6 The invention discloses the differential down-regulation of the sugar chain HexNAc(5)Hex(6)Fuc(1)NeuAc(3) on the glycosylation site N1055 of the aging-related glycoprotein Egfr in the brains of mice of different ages.

[0036] Figure 7 The invention discloses the up-regulated expression of phosphorylation site Y216 of aging-related phosphorylation protein Gsk3b in the brains of mice of different ages.

[0037] Figure 8The phosphorylation of HexNAc(2)Hex(9) on the glycosylation sites N348, HexNAc(5)Hex(3)Fuc(1) on N74, and HexNAc(6)Hex(3)Fuc(1) on N444 of the aging-related protein Grin2b obtained by the present invention was significantly downregulated, while the phosphorylation on S930 and S1303 was significantly upregulated. DETAILED DESCRIPTION

[0038] The technical solution adopted by the present invention is as follows:

[0039] The present invention provides a method for discovering aging biomarkers based on glycoproteomics and phosphoproteomics. In a first aspect, the present invention provides a sample pretreatment method for clinical biological samples, the sample pretreatment method comprising a protein extraction process, an enzymatic hydrolysis process, and a glycopeptide and phosphorylated peptide enrichment process of the clinical sample.

[0040] Wherein, the protein extraction process of the clinical sample is to perform ultrasonic crushing and protein extraction in a protein denaturing solution. The selected clinical samples should be tissues, body fluids, plasma, serum and cell lines of people or mammals of two or more age groups; the protein denaturing solution is a 5-100mM ammonium bicarbonate solution, which contains urea with a concentration of 0-8M, guanidine hydrochloride with a concentration of 0-8M, 0%-10% SDS as one or more combinations of denaturants and a protease inhibitor with a volume fraction of 1%-2%; the ultrasonic crushing of protein extraction is carried out in an ice bath, the ultrasonic power is 10-40W, the ultrasonic time is 2-5s, the interval time is 8-5s, and the total ultrasonic time is 3-10min. After the protein extraction process is completed, the obtained protein solution is centrifuged, the centrifugal speed is 10000-14000rpm, the centrifugal time is between 10-30min, and the obtained supernatant is the protein solution to be tested, and the concentration of the polypeptide sample is determined by the BCA protein assay.

[0041] Wherein, the proteolysis process of the clinical sample is to perform reduction alkylation and enzymolysis reaction on the obtained protein solution to be tested. The protein reduction process includes using a 5-100mM ammonium bicarbonate solution containing dithiothreitol (DTT) or tris (2-carboxyethyl) phosphine hydrochloride (TCEP) at a concentration of 5-50mM, and reacting for 5-120 minutes at room temperature or under heating conditions; the protein alkylation process includes using a 5-100mM ammonium bicarbonate solution containing iodoacetamide (IAA) or chloroacetamide (CAA) at a concentration of 5-50mM, and reacting for 5-60 minutes at room temperature in the dark; the proteolysis process includes adding enzymes according to the mass ratio of enzyme to protein of 1:1 1:50, the enzyme cutting time is 30min-24h, the types of proteases include one or more combinations of trypsin, chymotrypsin, lysyl endonuclease, thermolysin, proteinase K, and glutamyl protein endonuclease, and the temperature range of enzymolysis is the active temperature of the selected protease. After the enzyme digestion process is completed, a formic acid or trifluoroacetic acid solution with a volume fraction of 1-10% is used to terminate the enzyme digestion process to form an enzymatic polypeptide sample of the clinical sample.

[0042] The enrichment process of glycopeptides and phosphorylated peptides of the enzymatically hydrolyzed peptide samples of the clinical samples adopts solid phase extraction mode (SPE) or dispersed solid phase extraction mode (dSPE) to continuously enrich glycopeptides and phosphorylated peptides.

[0043] The glycopeptide enrichment material includes but is not limited to commercial ZIC-HILIC, amino silica material, Click-Mal material, Click-Cys material, etc. The material dosage is 1-10 mg; the mass ratio of the glycopeptide enrichment material to the enzymatic peptide sample of the clinical sample is 100:1-1000:1.

[0044] The specific steps of the glycopeptide enrichment process are as follows:

[0045] The enzymatic peptide sample is spin-dried and desalted by C18, then redissolved in the equilibrium solution, and the glycopeptide enrichment material is loaded into the pipette tip or gel loading tip to form an SPE solid phase extraction column. After balancing the material with a balancing solution, the enzymatic peptide sample is loaded into the SPE column, the balancing solution is an organic phase solution containing an organic acid, the volume concentration of the organic acid is 0.1-5%, the volume concentration of the organic phase is 60-95%, the organic acid is formic acid, acetic acid or trifluoroacetic acid, and the organic phase is acetonitrile, methanol or ethanol; the SPE column is rinsed with 5-200 times the column volume of the balancing solution to remove the phosphorylated peptides and non-modified peptides thereon; at the same time, the loading liquid and the eluent in the enrichment process are collected and combined; the glycopeptide is eluted with 5-100 times the column volume of a glycopeptide eluent, the glycopeptide eluent is an organic phase solution containing an organic acid, the volume concentration of the organic acid is 0.1-5%, the volume concentration of the organic phase is 20-55%, the organic acid is formic acid, acetic acid or trifluoroacetic acid, and the organic phase is acetonitrile, methanol or ethanol. Or when enriching glycopeptides in dSPE mode, the enzymatic peptide sample is directly mixed with the glycopeptide enrichment material, incubated for 0.5 minutes to 60 minutes, centrifuged, the material is rinsed with the balance solution, centrifuged, and the sample solution and the eluent in the enrichment process are collected and combined; the glycopeptide eluent is then used to elute the glycopeptide. The glycopeptide eluent obtained by solid phase extraction mode (SPE) or dispersed solid phase extraction mode (dSPE) is the glycoproteomics sample after spin drying.

[0046] The specific steps of the phosphorylated peptide enrichment process are as follows:

[0047] Wherein, the phosphorylated peptide enrichment materials include but are not limited to commercial IMAC, TiO 2 , ZrO 2 The amount of material used is 1-10 mg; the mass ratio of the phosphorylated peptide enrichment material to the enzymatic peptide sample of the initial clinical sample is 100:1-1000:1.

[0048] The phosphorylated peptide enrichment material is loaded into a pipette tip or a gel loading tip to form an SPE solid phase extraction column. The material is balanced with a balance solution, and the combined glycopeptide loading solution and eluent system are adjusted to a balance solution solvent system of the phosphorylated peptide material and then loaded into the SPE column, wherein the balance solution is an organic phase solution containing an organic acid, the volume concentration of the organic acid is 0.1-5%, the volume concentration of the organic phase is 60-95%, the organic acid is hydroxyacetic acid, formic acid, acetic acid or trifluoroacetic acid, and the organic phase is acetonitrile, methanol or ethanol; the SPE column is rinsed with 5-200 times the column volume of the balance solution to remove the non-modified peptides thereon; the phosphorylated peptide is eluted with 5-100 times the column volume of the phosphorylated peptide eluent, and the phosphorylated peptide eluent is a 0.5-30%wt ammonia solvent. Or when enriching phosphorylated peptides in dSPE mode, adjust the combined glycopeptide loading solution and eluent system to the equilibrium solution solvent system of phosphorylated peptide material and directly mix with phosphorylated peptide enriched material, incubate for 0.5 minutes to 60 minutes, centrifuge, rinse the material with equilibrium solution, centrifuge; then elute phosphorylated peptides with phosphorylated peptide eluent. The phosphorylated peptide eluent obtained by solid phase extraction mode (SPE) or dispersed solid phase extraction mode (dSPE) is the phosphorylated proteomics sample after spin drying.

[0049] In a first aspect, the present invention provides an analysis method for aging markers based on glycoproteomics and phosphoproteomics, including a liquid phase-tandem mass spectrometry analysis process, a database retrieval process, and a screening process for aging markers.

[0050] The liquid phase-tandem mass spectrometry separation and analysis process includes using any one of the Orbitrap series mass spectrometers of Thermo Fisher and the TIMS-TOF mass spectrometer of Bruker and a matching liquid chromatography system instrument; the liquid chromatography analysis column and pre-column use a conventional C18 capillary column, the capillary outer diameter is one of 100μm, 360μm, and 1mm, and the matching inner diameter is one of 10μm, 50μm, and 100μm; the capillary filling length is 10-50cm, and the C18 filler particles used are 1.7-5μm. The liquid mobile phase used is a mixed solvent of an organic solvent, deionized water, and an organic acid, wherein the organic acid is one of formic acid, acetic acid, or trifluoroacetic acid, and the volume proportion of the organic acid is 0.1%-30%; the volume proportion of the organic solvent is 1-80%; the chromatographic separation mode used is a reversed-phase chromatographic separation mode; the mass spectrometry data acquisition mode of glycoproteomics data is a data-dependent acquisition mode (DDA), and the data acquisition mode of phosphoproteomics data can be any one of a data-dependent acquisition mode (DDA) and a data-independent acquisition mode (DIA).

[0051] The database retrieval and analysis process includes the selection of retrieval software and data screening. The glycoproteomics data mass spectrometry data retrieval software uses one or several combinations of Byonic software from Protein Metrics or open source software such as pGlyco software; the phosphoproteomics data mass spectrometry data retrieval software uses one or several combinations of Maxquant, PD software from Thermo Fisher, Spectronaut software from Biognosys, or open source software such as DIA-NN; the database used is the species database corresponding to the samples used in UniProt.

[0052] The screening process of the aging markers includes filtering and interpolating missing values, log2 transformation, difference fold and significant difference analysis of the quantitative values ​​of the abundance of glycopeptides or phosphorylated peptides of different age sample groups obtained by the search software. The filtering of missing values ​​adopts the principle that at least one of the sample data between the two groups has more than half of the valid values; the interpolation of missing values ​​can adopt one of the K nearest neighbor method (KNN), continuous K nearest neighbor method (SeqKnn), global minimum, minimum value per row, multiple interpolation method (MI), random forest method (MissForest) and normal distribution method; the significance test adopts one of the EmpiricalBayes t test or Student's t test; the difference fold is obtained by filtering the missing values, interpolating and log2 transformation of the quantitative values ​​of the abundance of glycopeptides or phosphorylated peptides of different age sample groups. The peptides with |log2 fold change|>2 and p≤0.05 can be considered as peptides with age differences.

[0053] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention. If no specific techniques or conditions are specified in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used that do not specify the manufacturer are all conventional products that can be obtained commercially.

[0054] All % below without special remarks are volume percentages.

[0055] The preparation method of the homemade glycopeptide enrichment material Click-Mal can be referred to: Yu, XL Li, ZMGuo, XL Zhang, XMLiang, Hydrophililic Interaction Chromatography Based Enrichment of Glycopeptides by Using Click Maltose: A Matrix with High Selectivity and Glycosylation Heterogeneity Coverage, Chem.-Eur. J. 15 (46) (2009) 12618-12626.

[0056] Example 1

[0057] refer to Figure 1 , brain tissues of six mice (8 weeks and 65 weeks old) in each of two age groups were selected for parallel processing, with three technical replicates for each mouse. They were placed in 50mM ammonium bicarbonate solution (containing 8M urea) for ultrasonic disruption and protein extraction, with a total ultrasonic time of 3min, 3s ultrasonication, 7s interval, and 20w ultrasonic power. The obtained protein solution was centrifuged at 14000rpm for 10min, and the concentration of the supernatant was determined by BCA protein assay. A 50mM ammonium bicarbonate solution containing 5mM dithiothreitol (DTT) was added to the obtained protein solution, and the reaction was carried out at room temperature for 45 minutes; then a 50mM ammonium bicarbonate solution containing 10mM iodoacetamide (IAA) was added, and the reaction was carried out at room temperature in the dark for 30 minutes; then trypsin was added, and the mass ratio of the enzyme to the protein was 1:50, and the enzymatic hydrolysis was carried out at 37°C for 16h. After the enzymatic hydrolysis was completed, 5% formic acid was used to terminate the enzymatic hydrolysis, and the resulting solution was the proteolytic polypeptide sample of rat brain. The polypeptide sample was spin-dried and desalted with C18 and then redissolved in 80% ACN / 1% TFA solution.

[0058] Glycopeptide enrichment was performed using solid phase extraction mode. The material used was Click-Mal, a homemade glycopeptide enrichment material in the laboratory. 1.5 mg of Click-Mal material was loaded into an Eppendorf gun tip to make a micro SPE solid phase extraction column. The peptide sample was loaded into the SPE column, eluted 4 times with 50 μL 80% ACN / 1% TFA, and the loading effluent and the elution were collected and combined. 30% ACN / 1% FA 30 μL was used for elution 2 times, and the resulting glycopeptide eluate was the glycopeptide sample after spin drying.

[0059] The solid phase extraction mode was used for phosphorylated peptide enrichment. The material used was commercial IMAC material. 2.5 mg IMAC material was loaded into an Eppendorf gun head to make a micro SPE solid phase extraction column. 80% ACN / 2% TFA, 50 μL, was used to balance the IMAC material. The combined glycopeptide loading solution and eluent system were adjusted to 80% ACN / 2% TFA and then loaded into the SPE column. 80% ACN / 2% TFA, 50 μL, was used for 4 times of eluent, and 10% ammonia 30 μL was used for elution 2 times. The phosphorylated peptide eluent obtained was the phosphorylated peptide sample after being spin-dried.

[0060] Easy 1200 liquid phase and Orbitrap 480 mass spectrometer were used, equipped with a capillary column with a length of 20 cm and an outer diameter of 360 mm and filled with C18 reverse phase chromatography filler with a particle size of 1.9 mm as the analytical column, and equipped with a capillary column with a length of 2 cm and an outer diameter of 360 mm and filled with C18 reverse phase chromatography filler with a particle size of 1.9 mm as the pre-column. The liquid mobile phase A phase was 0.1% (volume fraction) formic acid, and the phase B was 0.1% (volume fraction) formic acid / 80% acetonitrile for reverse phase chromatography separation; the mass spectrometry data acquisition mode of glycoproteomics data was data dependent acquisition mode (DDA), and the data acquisition mode of phosphorylation proteomics was data independent acquisition mode (DIA). The commercialized Byonic software of Protein Metrics was used for glycopeptide mass spectrometry data retrieval software, and the Spectronaut software of Biognosys was used for phosphorylation proteomics data mass spectrometry data retrieval software; the database used was the UniProt-Mouse database.

[0061] The obtained glycoproteomics and phosphorylation proteomics search database data were grouped according to different ages. The data were filtered according to the data of at least one group of samples with more than half of the valid values; the missing values ​​were interpolated using the normal distribution interpolation method; the difference test was performed using Student's t test; the peptides with |log2 fold change|>2 and p≤0.05 can be considered as peptides with age differences. Among them, Figure 5-8 All of them are the glycoproteins and phosphorylated proteins with significant differences in aging detected in Example 1.

[0062] Example 2

[0063] The difference between Example 2 and Example 1 is that the sample pretreatment method in series with IMAC-HILIC is compared. The results are as follows: Figure 2 , Figure 3 and Figure 4As shown, it can be seen that the phosphorylated peptides in the glycopeptide fraction and the glycopeptides in the phosphorylated peptide fraction in the method provided by the present invention are lower than those in the sample pretreatment method of IMAC-HILIC in series, and the number of identified target peptides is higher than that in the sample pretreatment method of IMAC-HILIC in series. Therefore, it is also proved that the pretreatment method provided by the present invention can effectively improve the identification of post-translationally modified peptides and reduce cross-reactivity.

[0064] The protein extraction process, enzymatic hydrolysis process, liquid phase-tandem mass spectrometry analysis process, and database retrieval process of the sample pretreatment method of IMAC-HILIC tandem for comparison are consistent with the method of the present invention, and the only difference is the enrichment order of glycopeptides and phosphorylated peptides. The specific steps of enrichment of glycopeptides and phosphorylated peptides in the sample pretreatment method of IMAC-HILIC tandem are:

[0065] After protein extraction and enzymatic hydrolysis, the enzymatic peptide sample was redissolved in 80% ACN / 2% TFA, and the solid phase extraction mode was used for phosphorylated peptide enrichment. The material used was commercial IMAC material. 2.5 mg of IMAC material was loaded into the Eppendorf gun tip to make a micro SPE solid phase extraction column. Use 80% ACN / 2% TFA, 50 μL to balance the IMAC material. The enzymatic peptide sample was loaded into the SPE column, and 80% ACN / 2% TFA, 50 μL, was used for 4 times of elution. The sample effluent and the eluent were collected and combined. 10% ammonia water was used for elution twice, and the phosphorylated peptide eluate obtained was the phosphorylated peptide sample after spin drying.

[0066] The solid phase extraction mode was used for glycopeptide enrichment. The material used was Click-Mal, a homemade glycopeptide enrichment material in the laboratory. 1.5 mg of Click-Mal material was loaded into an Eppendorf gun tip to make a micro SPE solid phase extraction column. The combined phosphorylated peptide loading solution and eluent system was adjusted to 80% ACN / 1% TFA and loaded into the SPE column. 50 μL 80% ACN / 1% TFA was used for 4 times of elution. The loading effluent and eluent were collected and combined. 30% ACN / 1% FA was used for 30 μL of elution twice, and the resulting glycopeptide eluent was the glycopeptide sample after being spin-dried.

[0067] Under the premise that no conflict occurs, those skilled in the art may freely combine and superimpose the above-mentioned additional technical features.

[0068] The above-mentioned embodiments only express the preferred implementation modes of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the present invention. It should be pointed out that, for ordinary technicians in this field, various other corresponding changes and deformations can be made according to the technical solutions and concepts described above, and all these changes and deformations should fall within the scope of protection of the claims of the present invention.

Claims

1. A method for analyzing aging biomarkers based on glycoproteomics and phosphoproteomics, characterized in that: First, the clinical biological samples of different age groups were pre-treated to obtain glycoproteomics samples and phosphoproteomic samples. Liquid chromatography-mass spectrometry was used to detect and analyze the glycoproteomics samples and phosphoproteomic samples to obtain mass spectrometry data. Then, database retrieval, qualitative and quantitative analysis of glycopeptides and phosphopeptides were performed on the mass spectrometry data. Missing values ​​were filtered and interpolated, log2 transformed, and significant difference analysis was performed on the quantitative values ​​of glycopeptide or phosphopeptide abundance obtained from the database search. The pre-treatment of the clinical biological sample includes: a protein extraction process, an enzymatic hydrolysis process, and a glycopeptide and phosphorylated peptide enrichment process of the clinical biological sample.

2. The analysis method according to claim 1, characterized in that The clinical biological sample pretreatment specifically comprises the following steps: S1: Select clinical biological samples of different age groups, perform ultrasonic disruption and protein extraction in a protein denaturing solution, perform reduction alkylation reaction on the extracted proteins, and then add protease to enzymatically hydrolyze the samples to obtain enzymatic peptide samples of clinical biological samples; S2: After the enzymatic peptide sample is dried by spin drying and desalted by C18, it is redissolved in the equilibration liquid system, and the glycopeptide enrichment material is loaded into the pipette tip or gel loading tip to form an SPE solid phase extraction column; after the material is equilibrated with the equilibration liquid, the enzymatic peptide sample is loaded into the SPE column, and the SPE column is rinsed with 5-200 times the column volume of the equilibration liquid to remove the phosphorylated peptides and non-modified peptides thereon; at the same time, the loading liquid in the enrichment process is collected and combined with the eluent; the glycopeptide is eluted with 5-100 times the column volume of the glycopeptide eluent; or when enriching glycopeptides in the dSPE mode, the enzymatic peptide sample is directly mixed with the glycopeptide enrichment material, incubated for 0.5-60 minutes, centrifuged, the material is rinsed with the equilibration liquid, centrifuged, and the loading liquid in the enrichment process is collected and combined with the eluent; the glycopeptide is then eluted with the glycopeptide eluent; the glycopeptide eluent obtained by the solid phase extraction mode or the dispersed solid phase extraction mode is the glycoproteomics sample after spin drying; S3: Load the phosphorylated peptide enrichment material into the pipette tip or gel loading tip to form an SPE solid phase extraction column; use the equilibration liquid equilibration material to adjust the combined glycopeptide loading solution and eluent system in step S2 to the equilibration liquid solvent system of the phosphorylated peptide material, load it into the SPE column, and use 5-200 times the column volume of the equilibration liquid to wash the SPE column to remove the non-modified peptides thereon; use 5-100 times the column volume of the phosphorylated peptide eluent to elute the phosphorylated peptide; or when enriching phosphorylated peptides in the dSPE mode, adjust the combined glycopeptide loading solution and eluent system to the equilibration liquid solvent system of the phosphorylated peptide material and directly mix it with the phosphorylated peptide enrichment material, incubate for 0.5-60 minutes, centrifuge, wash the material with the equilibration liquid, and centrifuge; then use the phosphorylated peptide eluent to elute the phosphorylated peptide; the phosphorylated peptide eluent obtained by the solid phase extraction mode or the dispersed solid phase extraction mode is the phosphorylated proteomics sample after being spin-dried.

3. The analysis method according to claim 2, characterized in that In step S1, the clinical biological sample is at least one of a tissue, a body fluid, a plasma, a serum and a cell line of a mammal, and the mammals include at least two age groups.

4. The analysis method according to claim 2, characterized in that In step S1, at least one of the following technical features is included: The protein denaturing solution comprises at least one of a 5-100 mM ammonium bicarbonate solution, 0-8 M urea, 0-8 M guanidine hydrochloride, 0%-10% SDS, and a protease inhibitor with a volume fraction of 1-2%; The reductive alkylation reaction includes a reduction process and an alkylation process. The reduction process uses a 5-100 mM ammonium bicarbonate solution containing 5-50 mM dithiothreitol or tris(2-carboxyethyl)phosphine hydrochloride to react for 5-120 minutes at room temperature or under heating; the alkylation process specifically uses a 5-100 mM ammonium bicarbonate solution containing 5-50 mM iodoacetamide or chloroacetamide to react for 5-60 minutes at room temperature in the dark.

5. The analysis method according to claim 2, characterized in that In step S1, the protease is one or more combinations of trypsin, chymotrypsin, lysyl endonuclease, thermolysin, proteinase K, and glutamyl protein endonuclease; the mass ratio of protease to protein is controlled between 1:1-1:50; at the same time, the enzyme cleavage time is adjusted to 30min-24h; the enrichment process of glycopeptides and phosphorylated peptides adopts solid phase extraction mode or dispersed solid phase extraction mode.

6. The analysis method according to claim 2, characterized in that The glycopeptide enrichment material is a commercial hydrophilic chromatography material or a laboratory-made glycopeptide enrichment material; the amount of the glycopeptide enrichment material is 1-10 mg; the mass ratio of the glycopeptide enrichment material to the enzymatic peptide sample is 100:1-1000:1; The phosphorylated peptide enrichment material includes at least one of IMAC, TiO2, and ZrO2; the amount of the phosphorylated peptide enrichment material is 1-10 mg; the mass ratio of the phosphorylated peptide enrichment material to the enzymatic peptide sample of the initial clinical biological sample is 100:1-1000:

1.

7. The analysis method according to claim 2, wherein in step S2, the glycopeptide-enriched equilibrium solution is an organic phase solution containing an organic acid, the volume concentration of the organic acid is 0.1-5%, the volume concentration of the organic phase is 60-95%, the organic acid is formic acid, acetic acid or trifluoroacetic acid, and the organic phase is acetonitrile, methanol or ethanol; The glycopeptide enrichment eluent is an organic phase solution containing an organic acid, the volume concentration of the organic acid is 0.1-5%, the volume concentration of the organic phase is 20-55%, the organic acid is formic acid, acetic acid or trifluoroacetic acid, and the organic phase is acetonitrile, methanol or ethanol; The equilibrium solution for enriching phosphorylated peptides is an organic phase solution containing an organic acid, wherein the volume concentration of the organic acid is 0.1-5%, the volume concentration of the organic phase is 60-95%, the organic acid is glycolic acid, formic acid, acetic acid or trifluoroacetic acid, and the organic phase is acetonitrile, methanol or ethanol; The eluent for enriching phosphorylated peptides is 0.5-30% wt ammonia solvent.

8. The analysis method according to claim 1, characterized in that The liquid chromatography-mass spectrometry analysis process includes using Thermo Any mass spectrometer of Fisher's Orbitrap series mass spectrometer and Bruker's TIMS-TOF mass spectrometer and a matching liquid chromatography system instrument; the liquid chromatography analysis column and pre-column adopt a conventional C18 capillary column, the capillary outer diameter is one of 100μm, 360μm, and 1mm, and the matching inner diameter is one of 10μm, 50μm, and 100μm; the capillary filling length is 10-50cm, and the C18 filler particles used are 1.7-5μm; the liquid mobile phase used is a mixed solvent of organic solvent, deionized water, and organic acid, the organic acid is one of formic acid, acetic acid or trifluoroacetic acid, and the volume proportion of organic acid is 0.1%-30%; the volume proportion of organic solvent is 1-80%; the chromatographic separation mode used is a reversed phase chromatographic separation mode; the mass spectrometry data acquisition mode of glycoproteomics data is a data-dependent acquisition mode, and the data acquisition mode of phosphorylation proteomics is a data-dependent acquisition mode or a data-independent acquisition mode.

9. The analysis method according to claim 1, characterized in that The mass spectrometry data retrieval software for glycoproteomics data uses Byonic software from Protein Metrics or open source software; the mass spectrometry data retrieval software for phosphoproteomic data uses Maxquant, PD software from Thermo Fisher, Spectronaut software from Biognosys or open source software; the database used is the species database corresponding to the samples used in UniProt; The filtering of missing values ​​adopts the principle that at least one of the samples between the two groups has more than half of the valid values; the interpolation of missing values ​​adopts one of the following methods: K nearest neighbor method, continuous K nearest neighbor method, global minimum value, minimum value of each row, multiple interpolation method, random forest method and normal distribution method; The significant difference analysis was performed using Empirical Bayes t test or Student's t test; The fold difference was obtained by taking the ratio of the means of the quantitative values ​​of the abundance of glycopeptides or phosphorylated peptides in the sample groups of different ages after missing value filtering, interpolation and log2 transformation, where peptides with |log2 fold change|>2 and p≤0.05 were considered to be peptides with age differences.